Assignee
WUXI BIOLOGICS IRELAND LTD
IE·17 granted patents·43 pending applications·16 citations·filing 2016–2025
Top patents by PatentIndex Score
60 records- 0190US11795221B2Monoclonal antibody against human LAG-3, method for preparing the same, and use thereofWUXI BIOLOGICS IRELAND LTD·Filed 2019·Granted Oct 24, 2023·3 cites·19 claims
- 0289US11008391B2Anti-PD-1 antibodiesWUXI BIOLOGICS IRELAND LTD·Filed 2016·Granted May 18, 2021·4 cites·2 claims
- 0388US11478553B2Process for preparing antibody-drug conjugates with improved homogeneityWUXI BIOLOGICS IRELAND LTD·Filed 2020·Granted Oct 25, 2022·4 cites·22 claims
- 0486US11845796B2Bispecific polypeptide complexesWUXI BIOLOGICS IRELAND LTD·Filed 2018·Granted Dec 19, 2023·2 cites·27 claims
- 0580US11661452B2Anti-lag-3 antibody polypeptideWUXI BIOLOGICS IRELAND LTD·Filed 2019·Granted May 30, 2023·2 cites·22 claims
- 0676US2023348602A1Novel anti-pd-1 antibodiesWUXI BIOLOGICS IRELAND LTD·Filed 2023·Application pending·0 cites
- 0775US11774287B2Raman spectroscopy integrated perfusion cell culture system for monitoring and auto-controlling perfusion cell cultureWUXI BIOLOGICS IRELAND LTD·Filed 2020·Granted Oct 3, 2023·1 cites·20 claims
- 0874US2024124586A1Novel bispecific polypeptide complexesWUXI BIOLOGICS IRELAND LTD·Filed 2023·Application pending·0 cites
- 0973US2024301067A1Novel anti-pd-1 antibodiesWUXI BIOLOGICS IRELAND LTD·Filed 2024·Application pending·0 cites
- 1068US12485298B2Anti-CD3epsilon antibodiesWUXI BIOLOGICS IRELAND LTD·Filed 2022·Granted Dec 2, 2025·0 cites·19 claims
- 1165US2025313633A1Anti-B7H3 antibody and Uses thereofWUXI BIOLOGICS IRELAND LTD·Filed 2023·Application pending·0 cites
- 1262US12030941B2Anti-PD-1 antibodiesWUXI BIOLOGICS IRELAND LTD·Filed 2019·Granted Jul 9, 2024·0 cites·12 claims
- 1362US2025145679A1Heterodimeric polypeptide complexes comprising il-15 variants and uses thereofWUXI BIOLOGICS IRELAND LTD·Filed 2023·Application pending·0 cites
- 1461US12570746B2Anti-PD-L1 antibodiesWUXI BIOLOGICS IRELAND LTD·Filed 2020·Granted Mar 10, 2026·0 cites·18 claims
- 1561US2026062661A1Intermittent perfusion fed-batch cultureWUXI BIOLOGICS IRELAND LTD·Filed 2022·Application pending·0 cites
- 1661US2025000946A1Il-2 variants and fusion proteins thereofWUXI BIOLOGICS IRELAND LTD·Filed 2022·Application pending·0 cites
- 1760US2024285685A1Genetically modified nk cells and uses thereofWUXI BIOLOGICS IRELAND LTD·Filed 2022·Application pending·0 cites
- 1860US2023008090A1A novel anti-cd3/anti-egfr bispecific antibody and uses thereofWUXI BIOLOGICS IRELAND LTD·Filed 2020·Application pending·0 cites
- 1959US12486325B2Anti-CD3epsilon antibodiesWUXI BIOLOGICS IRELAND LTD·Filed 2022·Granted Dec 2, 2025·0 cites·20 claims
- 2059US2025026833A1A bispecific anti-pd-l1/vegf antibody and uses thereofWUXI BIOLOGICS IRELAND LTD·Filed 2022·Application pending·0 cites
- 2158US2024239885A1Antibody conjugate comprising anti-p-cadherin antibody and uses thereofWUXI BIOLOGICS IRELAND LTD·Filed 2022·Application pending·0 cites
- 2258US2024317872A1Polypeptide complexes with improved stability and expressionWUXI BIOLOGICS IRELAND LTD·Filed 2022·Application pending·0 cites
- 2357US2023047549A1An apparatus and a method for continuously harvesting a biological substance produced by a cultured cellWUXI BIOLOGICS IRELAND LTD·Filed 2021·Application pending·0 cites
- 2457US2025066711A1Method for collecting microbial bodies from fermentation solution suitable for automatic operationWUXI BIOLOGICS IRELAND LTD·Filed 2022·Application pending·0 cites
- 2556US11440962B2Anti-CD3epsilon antibodiesWUXI BIOLOGICS IRELAND LTD·Filed 2018·Granted Sep 13, 2022·0 cites·19 claims
- 2656US2025215109A1Anti-her2/anti-cd47 molecules and uses thereofWUXI BIOLOGICS IRELAND LTD·Filed 2023·Application pending·0 cites
- 2756US2022127637A1Transcriptional regulatory element and its use in enhancing the expression of heterologous proteinWUXI BIOLOGICS IRELAND LTD·Filed 2022·Application pending·0 cites
- 2856US2024034786A1An antibody against p-cadherin and uses thereofWUXI BIOLOGICS IRELAND LTD·Filed 2021·Application pending·0 cites
- 2955US12202894B2Anti-TIM-3 antibodiesWUXI BIOLOGICS IRELAND LTD·Filed 2019·Granted Jan 21, 2025·0 cites·23 claims
- 3055US2025277054A1Psma antibodies and uses thereofWUXI BIOLOGICS IRELAND LTD·Filed 2025·Application pending·0 cites
- 3155US2024376194A1D3-binding molecules and uses thereofWUXI BIOLOGICS IRELAND LTD·Filed 2022·Application pending·0 cites
- 3255US2024076411A1Multispecific antigen binding proteinsWUXI BIOLOGICS IRELAND LTD·Filed 2021·Application pending·0 cites
- 3355US2023391846A1Modified soluble t cell receptorWUXI BIOLOGICS IRELAND LTD·Filed 2021·Application pending·0 cites
- 3454US11773172B2Anti-EGFR antibody polypeptideWUXI BIOLOGICS IRELAND LTD·Filed 2019·Granted Oct 3, 2023·0 cites·7 claims
- 3554US2023270823A1Long-acting il-15 and uses thereofWUXI BIOLOGICS IRELAND LTD·Filed 2021·Application pending·0 cites
- 3654US2025035628A1BIOASSAYS TO MEASURE THE SYNERGISTIC ANTIBODY-DEPENDENT ENHANCEMENT (ADE) EFFECT OF SARS-CoV-2 NEUTRALIZING ANTIBODIESWUXI BIOLOGICS IRELAND LTD·Filed 2022·Application pending·0 cites
- 3753US2025035613A13d bioassays to measure antibody-dependent cell-mediated cytotoxicityWUXI BIOLOGICS IRELAND LTD·Filed 2022·Application pending·0 cites
- 3853US2022017462A1Ortho-phthalaldehyde containing linkers and use for preparation of antibody-drug conjugateWUXI BIOLOGICS IRELAND LTD·Filed 2019·Application pending·0 cites
- 3952US2022348664A1A novel anti-pd-l1/anti-lag-3 bispecific antibody and uses thereofWUXI BIOLOGICS IRELAND LTD·Filed 2020·Application pending·0 cites
- 4052US2023072133A1A bifunctional fusion protein and uses thereofWUXI BIOLOGICS IRELAND LTD·Filed 2021·Application pending·0 cites
- 4151US2023203530A1Enhanced expression system and methods of use thereofWUXI BIOLOGICS IRELAND LTD·Filed 2021·Application pending·0 cites
- 4251US2023035169A1BI-FUNCTIONAL ANTIBODY AGAINST PD-L1 AND TGF-BetaWUXI BIOLOGICS IRELAND LTD·Filed 2020·Application pending·0 cites
- 4350US2022213192A1Bispecific antibodies against pd-1 and lag-3WUXI BIOLOGICS IRELAND LTD·Filed 2020·Application pending·0 cites
- 4450US2024167010A9A genetically modified cell line producing a recombinant glycoprotein having a mannose-terminated n-glycanWUXI BIOLOGICS IRELAND LTD·Filed 2021·Application pending·0 cites
- 4549US2022162312A1Novel bispecific cd3/cd20 polypeptide complexesWUXI BIOLOGICS IRELAND LTD·Filed 2020·Application pending·0 cites
- 4649US2021380638A1A method for improving aggregate removal by Protein A chromatographyWUXI BIOLOGICS IRELAND LTD·Filed 2019·Application pending·0 cites
- 4749US2022267467A1Polypeptide complex for conjugation and use thereofWUXI BIOLOGICS IRELAND LTD·Filed 2020·Application pending·0 cites
- 4848US2023092867A1A novel wash buffer solution for affinity chromatographyWUXI BIOLOGICS IRELAND LTD·Filed 2021·Application pending·0 cites
- 4947US2021115138A1Novel bispecific pd-1/lag-3 antibody moleculesWUXI BIOLOGICS IRELAND LTD·Filed 2019·Application pending·0 cites
- 5047US2021340252A1Anti-tim-3 antibodies and uses thereofWUXI BIOLOGICS IRELAND LTD·Filed 2019·Application pending·0 cites
Showing the top 50 of 60 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when WUXI BIOLOGICS IRELAND LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →